Belfast Clinical Trial Combining Two Radio-Therapies For Men With Advanced Prostate Cancer
Researchers at Queen’s University in Belfast along with the Belfast Trust are conducting a clinical trial evaluating the combination of two radiotherapy treatments, Radium 223 and Pelvic Radiation using Volumetric Modulated Arc Therapy (VMAT) in [...]
Levels of Serum Alkaline Phosphatase Reflect Negative Prostate Cancer Bone Activity
Not often discussed, but a valuable measure of prostate cancer bone activity is serum (in the blood) alkaline phosphatase. It is a normal enzyme produced naturally by the body. Everyone produces some of this enzyme regardless [...]
Comparison Evaluating Bone Mineral Density Changes in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol
The current standard hormone therapy (ADT) for men with advanced prostate cancer is a class of drugs called Luteinising hormone-releasing hormone agonists (LHRHa). These drugs reduce serum oestradiol as well as testosterone, causing bone mineral [...]
Real Life Issues About Abiraterone Acetate (Zytiga) Prior to Chemotherapy – Unanticipated Real-World Clinical Experience Worth Noting
Researchers in Hong Kong wanted to confirm the efficacy of abiraterone acetate (Zytiga) used prior to chemotherapy that had been shown in the trial setting. In their analysis they came up short; raising some very [...]
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Phase II Results
We know that prostate cancer is a heterogeneous disease, but most of our treatments are not based on the different molecular stratification exhibited by the disease. One of the differences we do recognize in the [...]
A new Trend – Chemotherapy for Metastatic Castrate-Sensitive Prostate Cancer
Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men [...]